US 12,258,579 B2
Mammalian cell population and medicaments for cell therapies in humans and improved cell cultivation methods
Antoine Lafont, Paris (FR); and Mathieu Castela, Clamart (FR)
Assigned to Scarcell Technologies, Paris (FR)
Filed by SCARCELL Therapeutics, Paris (FR)
Filed on Apr. 17, 2023, as Appl. No. 18/301,839.
Claims priority of provisional application 63/490,489, filed on Mar. 15, 2023.
Claims priority of application No. 23305350 (EP), filed on Mar. 15, 2023.
Prior Publication US 2024/0309323 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61K 9/08 (2006.01); A61K 35/33 (2015.01); A61K 35/38 (2015.01); A61K 45/06 (2006.01); A61P 19/00 (2006.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01)
CPC C12N 5/0632 (2013.01) [A61K 9/08 (2013.01); A61K 35/28 (2013.01); A61K 35/33 (2013.01); A61K 35/38 (2013.01); A61K 45/06 (2013.01); A61P 19/00 (2018.01); C12N 5/0656 (2013.01); C12N 5/0692 (2013.01); C12N 2500/32 (2013.01); C12N 2500/84 (2013.01); C12N 2501/115 (2013.01); C12N 2501/2301 (2013.01); C12N 2509/00 (2013.01)] 13 Claims
 
1. A composition comprising a conditioned medium derived from a cultured human gingival fibroblast cell population, sodium hyaluronate, sodium chloride, disodium phosphate and monosodium phosphate, wherein the cultured human gingival fibroblast cell population is cultivated so that at least about 90% of the cells of the population express CD90 and CD63 and about 20% or less of the cells of the population express CD146, and wherein the conditioned medium comprises paracrine secretions by the human gingival fibroblast cell population cultured in a medium comprising a buffering agent, L-glutamine, sodium bicarbonate, sodium pyruvate, hypoxanthine, thymidine, and growth factors, for at least 24 hours.